FLSM
GRCL

Frazier Life Sciences Management’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

Frazier Life Sciences Management’s Portfolio GRCL Stock Details GRCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,890,102
Closed -$9.31M – 46
2022
Q3 		$9.31M Sell
2,890,102
-221,449
-7% -$720K 0.72% 30
2022
Q2 		$17.1M Sell
3,111,551
-334,422
-10% -$1.04M 1.62% 17
2022
Q1 		$8.03M Buy
+3,445,973
New +$11.7M 0.68% 32

Other funds holding GRCL

Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
CII
Capital International Inc Los Angeles, California $14.3B AUM 34.19% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $7.06B AUM 36.47% 1-Year Est. Return

Frazier Life Sciences Management's GRCL Position: Q4 2022 in Review

Frazier Life Sciences Management sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q4 2022, closing a stake of 2,890,102 shares — an estimated $9.31M sold.

Frazier Life Sciences Management first reported a position in GRCL in Q1 2022 and held it in 3 quarters. The position peaked at $17.1M in Q2 2022. 33 funds tracked by Wall St. Rank hold GRCL as of Q4 2022.

  • Frazier Life Sciences Management reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q4 2022 after selling out during the quarter.
  • Frazier Life Sciences Management sold 2,890,102 Gracell Biotechnologies Inc. American Depositary Shares shares in Q4 2022, an estimated $9.31M.
  • Frazier Life Sciences Management first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q1 2022 and held it in 3 quarters.
  • Frazier Life Sciences Management's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $17.1M in Q2 2022.
  • 33 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q4 2022.

Based on Frazier Life Sciences Management's 13F filing for Q4 2022, filed 3 Feb 2023.